The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine:
AST/ALT
De Ritis ratio
biomarker
gemcitabine
nab-paclitaxel
pancreatic cancer
treatment response
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
07
2019
accepted:
19
12
2019
entrez:
22
4
2020
pubmed:
22
4
2020
medline:
22
4
2020
Statut:
epublish
Résumé
The pretreatment De Ritis ratio [aspartate transaminase (AST)/alanine transaminase (ALT)] has been shown to be an adverse prognostic marker in various cancer entities. However, its relevance to advanced pancreatic ductal adenocarcinoma (PDAC) has not yet been studied. In the present study we investigated the AST/ALT ratio as a possible predictor of treatment response and disease outcome in patients with advanced PDAC treated with first-line gemcitabine/nab-paclitaxel. A Median and 1-year progression-free survival estimates were 4.8 months and 5.1%, respectively in patients with an AST/ALT ratio above the 75th percentile of its distribution, and 6.0 months and 18.7%, respectively in patients with an AST/ALT ratio less than or equal to this cutoff, respectively (log-rank The pretreatment serum AST/ALT ratio predicts poor disease outcome and response rate in patients with advanced PDAC treated with gemcitabine/nab-paclitaxel and might represent a novel and inexpensive marker for individual risk assessment in the treatment of pancreatic cancer.
Sections du résumé
BACKGROUND
BACKGROUND
The pretreatment De Ritis ratio [aspartate transaminase (AST)/alanine transaminase (ALT)] has been shown to be an adverse prognostic marker in various cancer entities. However, its relevance to advanced pancreatic ductal adenocarcinoma (PDAC) has not yet been studied. In the present study we investigated the AST/ALT ratio as a possible predictor of treatment response and disease outcome in patients with advanced PDAC treated with first-line gemcitabine/nab-paclitaxel.
METHODS
METHODS
A
RESULTS
RESULTS
Median and 1-year progression-free survival estimates were 4.8 months and 5.1%, respectively in patients with an AST/ALT ratio above the 75th percentile of its distribution, and 6.0 months and 18.7%, respectively in patients with an AST/ALT ratio less than or equal to this cutoff, respectively (log-rank
CONCLUSIONS
CONCLUSIONS
The pretreatment serum AST/ALT ratio predicts poor disease outcome and response rate in patients with advanced PDAC treated with gemcitabine/nab-paclitaxel and might represent a novel and inexpensive marker for individual risk assessment in the treatment of pancreatic cancer.
Identifiants
pubmed: 32313566
doi: 10.1177/1758835919900872
pii: 10.1177_1758835919900872
pmc: PMC7153180
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835919900872Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare that they have no competing interests.
Références
Clin Cancer Res. 2016 Jan 1;22(1):200-6
pubmed: 26302981
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
PLoS One. 2016 Oct 12;11(10):e0164057
pubmed: 27732629
Urol Oncol. 2016 Sep;34(9):417.e9-417.e15
pubmed: 27180325
Int Urol Nephrol. 2017 Aug;49(8):1391-1398
pubmed: 28550473
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Exp Ther Med. 2012 Mar;3(3):423-432
pubmed: 22969906
Oncologist. 2015 Feb;20(2):143-50
pubmed: 25582141
Br J Cancer. 2008 Sep 16;99(6):883-93
pubmed: 19238630
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
Int J Mol Sci. 2016 Jun 09;17(6):
pubmed: 27294917
Int Urol Nephrol. 2017 Sep;49(9):1577-1583
pubmed: 28669104
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
BMC Cancer. 2017 Aug 14;17(1):544
pubmed: 28806937
Clin Genitourin Cancer. 2017 Oct;15(5):598-604
pubmed: 28495053
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
J Urol. 2015 Jul;194(1):30-5
pubmed: 25623738
Eur J Cancer. 2016 Sep;65:11-20
pubmed: 27451020
Clin Chim Acta. 1957 Feb;2(1):70-4
pubmed: 13447217
Nature. 2013 Apr 4;496(7443):101-5
pubmed: 23535601
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087